Victor L. Villemagne

Active 1987–2025

266
Papers
40,295
Citations
106
h-index
247
i10-index

Citations

Citations per year for Victor L. Villemagne1967: 1 citations1971: 1 citations1988: 1 citations1990: 1 citations1991: 3 citations1992: 1 citations1993: 1 citations1994: 2 citations1995: 1 citations1996: 2 citations1997: 8 citations1998: 8 citations1999: 23 citations2000: 44 citations2001: 54 citations2002: 53 citations2003: 60 citations2004: 66 citations2005: 73 citations2006: 41 citations2007: 75 citations2008: 135 citations2009: 162 citations2010: 186 citations2011: 328 citations2012: 363 citations2013: 458 citations2014: 501 citations2015: 489 citations2016: 528 citations2017: 537 citations2018: 680 citations2019: 1,449 citations2020: 1,636 citations2021: 1,898 citations2022: 1,727 citations2023: 1,657 citations2024: 2,464 citations2025: 1,624 citations2026: 80 citations1968–1970: no citations, so these years are not shown1972–1987: no citations, so these years are not shown1989: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,126 citing papers, 24.9% of this breakdownUnited Kingdom: 1,814 citing papers, 8.8% of this breakdownChina: 1,658 citing papers, 8.1% of this breakdownAustralia: 1,156 citing papers, 5.6% of this breakdownSweden: 1,044 citing papers, 5.1% of this breakdownGermany: 1,005 citing papers, 4.9% of this breakdownCanada: 751 citing papers, 3.6% of this breakdownItaly: 702 citing papers, 3.4% of this breakdownFrance: 697 citing papers, 3.4% of this breakdownNetherlands: 685 citing papers, 3.3% of this breakdownSpain: 683 citing papers, 3.3% of this breakdownJapan: 490 citing papers, 2.4% of this breakdown
0%24.9%Other 23.2%

Fields

  • Medicine65.8%
  • Neuroscience16.9%
  • Biochemistry, Genetics and Molecular Biology9.6%
  • Computer Science1.6%
  • Psychology1.2%
  • Engineering0.8%
  • Other4.1%

Topics

  • Alzheimer's disease research and treatments16.3%
  • Dementia and Cognitive Impairment Research12.8%
  • Functional Brain Connectivity Studies3.3%
  • Neuroinflammation and Neurodegeneration Mechanisms2.4%
  • Parkinson's Disease Mechanisms and Treatments2.1%
  • Advanced Neuroimaging Techniques and Applications1.8%
  • Other61.3%

Coauthors

All papers

Open in search
  1. The Amyloid-β Pathway in Alzheimer’s Disease

    Authors: , , , , , , , , , , , , , , - Molecular Psychiatry 2021 cited by 1,806

  2. High performance plasma amyloid-β biomarkers for Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , - Nature 2018 cited by 1,721

  3. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

    Authors: , , , , , , , , , , , , - The Lancet Neurology 2013 cited by 2,291

  4. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , , , , , - International Psychogeriatrics 2009 cited by 982

  5. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas K. Karikari, Pedro Rosa‐Neto, Tharick A. Pascoal - Nature Medicine 2023 cited by 310

  6. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , - Translational Psychiatry 2021 cited by 460

  7. Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort

    Authors: , , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2022 cited by 288

  8. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Drzezga - The Lancet Neurology 2020 cited by 531

  9. Multisite study of the relationships between antemortem [11C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Salvatore Spina, Prashanthi Vemuri, Victor L. Villemagne, Melissa E. Murray, Gil D. Rabinovici - Alzheimer s & Dementia 2018 cited by 326

  10. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2021 cited by 235

  11. Prevalence of Amyloid PET Positivity in Dementia Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Koen Van Laere, Alexander Drzezga, Stefan Förster, Timo Grimmer, Pascual Sánchez‐Juan, J.M. Carril, Vincent Mok, Vincent Camus, William E. Klunk, Ann D. Cohen, Philipp T. Meyer, Sabine Hellwig, Andrew B. Newberg, Kristian Steen Frederiksen, Adam Fleisher, Mark A. Mintun, David A. Wolk, Agneta Nordberg, Juha O. Rinne, Gaël Chételat, Alberto Lleó, Rafael Blesa, Juan Fortea, Karine Madsen, Karen M. Rodrigue, David J. Brooks - JAMA 2015 cited by 666

  12. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2019 cited by 301

  13. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cynthia Picard, David Maillet, Diane Michaud, Doris Couture, Doris Dea, A. Claudio Cuello, Alan Barkun, Alan C. Evans, Blandine Courcot, Christine Tardif, Clément Debacker, Clifford R. Jack, David Fontaine, David S. Knopman, Gerhard Multhaup, Jamie Near, Jeannie‐Marie Leoutsakos, Jean‐Robert Maltais, Jason Brandt, Jens C. Pruessner, John C. Morris, John C.S. Breitner, Judes Poirier, Laksanun Cheewakriengkrai, Lisa-Marie MÃ ⁄ nter, D. Louis Collins, M. Mallar Chakravarty, Mark A. Sager, Marina Dauar‐Tedeschi, Mark J. Eisenberg, Natasha Rajah, Paul Aisen, Paule‐Joanne Toussaint, Pedro Rosa‐Neto, Pierre Bellec, Penelope Kostopoulos, Pierre Étienne, Pierre N. Tariot, Pierre Orban, Reisa A. Sperling, Rick Hoge, Ronald G. Thomas, Serge Gauthier, Suzanne Craft, Sylvia Villeneuve, Thomas J. Montine, Vasavan Nair, Véronique D. Bohbot, Vinod Venugopalan, Vladimir Fonov, Yasser Ituria‐Medina, Zaven S. Khachaturian, Eduard Teigner, Elena Anthal, Elsa Yu, Fabiola Ferdinand, Galina Pogossova, Ginette Mayrand, Guerda Duclair, Guylaine Gagné, Holly Newbold‐Fox, Illana Leppert, Isabelle Vallée, Jacob W. Vogel, Jennifer Tremblay‐Mercier, Joanne Frenette, Josée Frappier, Justin Kat, Justin Miron, Karen Wan and 99 more - JAMA Neurology 2022 cited by 133

  14. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

    Authors: , , , , - Nature Reviews Neurology 2018 cited by 437

  15. A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2023 cited by 90

  16. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults

    Authors: , , , , , , , , , , , , , , , , , , , , - JAMA Neurology 2019 cited by 373

  17. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S. Lance Macaulay, Lucy Mackintosh, Ralph N. Martins, Paul Maruff, Colin L. Masters, Simon McBride, Lidija Milicic, Madeline Peretti, Kelly Pertile, Tenielle Porter, Morgan Radler, Alan Rembach, Joanne Robertson, Mark Rodrigues, Christopher C. Rowe, Rebecca Rumble, Olivier Salvado, Greg Savage, Brendan Silbert, Magdalene Soh, Hamid R. Sohrabi, Kevin Taddei, Tania Taddei, Christine Thai, Brett Trounson, Regan Tyrrell, Michaël Vacher, Shiji Varghese, Victor L. Villemagne, Michael Weinborn, Mark Woodward, Ying Xia, David Ames, the AIBL investigators - Journal of Alzheimer s Disease Reports 2021 cited by 177

  18. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kai Bötzel, Joseph Claßen, Peter Bartenstein, Victor L. Villemagne, Johannes Levin, Günter U. Höglinger, Alexander Drzezga, John Seibyl, Osama Sabri - JAMA Neurology 2020 cited by 253

  19. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eduardo R. Zimmer, Pedro Rosa‐Neto, Tharick A. Pascoal - Molecular Psychiatry 2022 cited by 147

  20. Tau deposition patterns are associated with functional connectivity in primary tauopathies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jost J. Rumpf, Matthias L. Schroeter, Joseph Claßen, Victor L. Villemagne, John Seibyl, Andrew Stephens, Edward B. Lee, David G. Coughlin, Armin Giese, Murray Grossman, Corey T. McMillan, Ellen Gelpí, Laura Molina‐Porcel, Yaroslau Compta, John C. van Swieten, Laura Donker Laat, Claire Troakes, Safa Al‐Sarraj, John Robinson, Sharon X. Xie, David J. Irwin, Sigrun Roeber, Jochen Herms, Mikael Simons, Peter Bartenstein, Virginia M. Lee, John Q. Trojanowski, Johannes Levin, Günter U. Höglinger, Michael Ewers - Nature Communications 2022 cited by 108

  21. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment

    Authors: , , , , , , , , , , - Molecular Psychiatry 2014 cited by 407

  22. Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine Thai, Brett Trounson, Kate Lennon, Qiao‐Xin Li, Fernanda Yevenes Ugarte, Irene Volitakis, Michael Vovos, Rob Williams, Jenalle E. Baker, Alyce Russell, Madeline Peretti, Lidija Milicic, Lucy Lim, Mark Rodrigues, Kevin Taddei, Tania Taddei, Eugene Hone, Florence Lim, Shane Fernandez, Stephanie R. Rainey‐Smith, Steve Pedrini, Ralph N. Martins, James D. Doecke, Pierrick Bourgeat, Jürgen Fripp, Simon Gibson, Hugo Leroux, David G. Hanson, Vincent Doré, Ping Zhang, Samantha C. Burnham, Christopher C. Rowe, Victor L. Villemagne, Paul Yates, Sveltana Bozin Pejoska, Gareth Jones, David Ames, Elizabeth Cyarto, Nicola T. Lautenschlager, Kevin J. Barnham, Lesley Cheng, Andy Hill, Neil Killeen, Paul Maruff, Brendan Silbert, Belinda M. Brown, Hamid R. Sohrabi, Greg Savage, Michaël Vacher - Nature Communications 2021 cited by 147

  23. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

    Authors: , , , , , , , , , , , , , , , , , , , , , - Neurobiology of Aging 2010 cited by 993

  24. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

    Authors: , , , , , , , , , , , - Alzheimer s Research & Therapy 2020 cited by 177